{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:56:14Z","timestamp":1792151774632,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Flap endonuclease 1 (FEN1), a key enzyme in DNA metabolism, exhibits oncogenic properties in various cancers. However, its functional role and underlying mechanisms in lung adenocarcinoma (LUAD) progression and tumor immunity remain poorly defined. Here, we demonstrate that FEN1 is significantly upregulated in LUAD tissues and serves as an independent prognostic factor for poor survival. Genetic depletion of FEN1 suppressed LUAD cell proliferation by inducing G0\/G1 cell cycle arrest and cellular senescence, while significantly impairing migration and invasion capabilities. Mechanistically, integrated proteomic and molecular analyses revealed that FEN1 knockdown disrupts the carboxyl-terminal subunit of mucin 1 (MUC1-C)\/PI3K\/AKT autoregulatory loop, a critical driver of oncogenic signaling. Furthermore, FEN1 downregulation inhibited the MUC1-C\/p65\/ programmed death-ligand 1 (PD-L1) signaling axis, thereby alleviating tumor-mediated immunosuppression. This was evidenced by enhanced antitumor immunity, characterized by the local expansion of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells and restored effector function of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, both in vitro and in vivo. Mechanistically, independent of its nuclease activity, FEN1 interacts with the N-terminus of eukaryotic translation initiation factor 4A3 (EIF4A3) to facilitate its binding to MUC1-C mRNA. Specifically, FEN1 is required for EIF4A3-mediated maintenance of both the transcript stability and translation efficiency of MUC1-C. Clinically, FEN1, MUC1-C, and PD-L1 are coordinately upregulated in LUAD tissues, and their co-expression predicts poor patient survival irrespective of EGFR mutation status. Our findings establish the FEN1\/EIF4A3\/MUC1-C axis as a novel mechanism driving LUAD progression by concurrently regulating intrinsic malignancy and extrinsic immune evasion, presenting FEN1 targeting as a promising dual-hit therapeutic strategy.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09260-5","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:16:04Z","timestamp":1788624964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting FEN1 disrupts EIF4A3-mediated MUC1-C autoregulation: a novel strategy to suppress lung adenocarcinoma progression"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9920-5721","authenticated-orcid":false,"given":"Min","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benmeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-5907","authenticated-orcid":false,"given":"Xuebing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8153-6653","authenticated-orcid":false,"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"9260_CR1","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","volume":"13","author":"G Luo","year":"2025","unstructured":"Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025;13:348\u201363.","journal-title":"Lancet Respir Med"},{"key":"9260_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020;383:640\u20139.","journal-title":"N Engl J Med"},{"key":"9260_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Guidelines\u00ae Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 2023;21:340\u201350.","journal-title":"J Natl Compr Canc Netw"},{"key":"9260_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404:803\u201322.","journal-title":"Lancet"},{"key":"9260_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13046-025-03462-z","volume":"44","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Shen Y, Che Y, Jia L, Xiao X, Xu H, et al. Hypoxia-inducible APCDD1L-AS1 promotes osimertinib resistance by stabilising DLST to drive tricarboxylic acid cycle in lung adenocarcinoma. J Exp Clin Cancer Res. 2025;44:197.","journal-title":"J Exp Clin Cancer Res"},{"key":"9260_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/nar\/gkq884","volume":"39","author":"L Zheng","year":"2011","unstructured":"Zheng L, Jia J, Finger LD, Guo Z, Zer C, Shen B. Functional regulation of FEN1 nuclease and its link to cancer. Nucleic Acids Res. 2011;39:781\u201394.","journal-title":"Nucleic Acids Res"},{"key":"9260_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nm1599","volume":"13","author":"L Zheng","year":"2007","unstructured":"Zheng L, Dai H, Zhou M, Li M, Singh P, Qiu J, et al. Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med. 2007;13:812\u20139.","journal-title":"Nat Med"},{"key":"9260_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.7150\/ijbs.68179","volume":"18","author":"S Bian","year":"2022","unstructured":"Bian S, Ni W, Zhu M, Zhang X, Qiang Y, Zhang J, et al. Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7\/MDM2-mediated P53 Inactivation. Int J Biol Sci. 2022;18:1022\u201338.","journal-title":"Int J Biol Sci"},{"key":"9260_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.dld.2023.08.050","volume":"56","author":"X Yuwei","year":"2024","unstructured":"Yuwei X, Bingzi D, Zhaowei S, Yujie F, Wei Z, Kun L, et al. FEN1 promotes cancer progression of cholangiocarcinoma by regulating the Wnt\/\u03b2-catenin signaling pathway. Dig Liver Dis. 2024;56:695\u2013704.","journal-title":"Dig Liver Dis"},{"key":"9260_CR10","doi-asserted-by":"crossref","unstructured":"Yang F, Hu Z, Guo Z Small-Molecule Inhibitors Targeting FEN1 for Cancer Therapy. Biomolecules. 2022;12.","DOI":"10.3390\/biom12071007"},{"key":"9260_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41388-019-0986-0","volume":"39","author":"X Lu","year":"2020","unstructured":"Lu X, Liu R, Wang M, Kumar AK, Pan F, He L, et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer. Oncogene. 2020;39:234\u201347.","journal-title":"Oncogene"},{"key":"9260_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06216-9","volume":"23","author":"M Wu","year":"2025","unstructured":"Wu M, Wu B, Huang X, Wang Z, Zhu M, Zhu Y, et al. Inhibition of the FEN1-PBX1 axis elicits cellular senescence in breast cancer via the increased intracellular reactive oxygen species levels. J Transl Med. 2025;23:248.","journal-title":"J Transl Med"},{"key":"9260_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41368-023-00221-8","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Wang X, Sun J, Yang J, Wu D, Wu F, et al. Down-regulation of DNA key protein-FEN1 inhibits OSCC growth by affecting immunosuppressive phenotypes via IFN-\u03b3\/JAK\/STAT-1. Int J Oral Sci. 2023;15:17.","journal-title":"Int J Oral Sci"},{"key":"9260_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/jop.13485","volume":"52","author":"X Wang","year":"2023","unstructured":"Wang X, Xu S, Fu T, Wu Y, Sun W. Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+ T cells against HNSCC cells in vitro. J Oral Pathol Med. 2023;52:834\u201342.","journal-title":"J Oral Pathol Med"},{"key":"9260_CR15","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/neuonc\/noad115","volume":"25","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Gu S, Li L, Zhao R, Xie S, Zhang J, et al. A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma. Neuro Oncol. 2023;25:2207\u201320.","journal-title":"Neuro Oncol"},{"key":"9260_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","volume":"70","author":"CL Hattrup","year":"2008","unstructured":"Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431\u201357.","journal-title":"Annu Rev Physiol"},{"key":"9260_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbcan.2017.03.003","volume":"1868","author":"H Rajabi","year":"2017","unstructured":"Rajabi H, Kufe D. MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta Rev Cancer. 2017;1868:117\u201322.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"9260_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2313671","volume":"56","author":"H Xu","year":"2024","unstructured":"Xu H, Du Z, Li Z, Liu X, Li X, Zhang X, et al. MUC1-EGFR crosstalk with IL-6 by activating NF-\u03baB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma. Ann Med. 2024;56:2313671.","journal-title":"Ann Med"},{"key":"9260_CR19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/onc.2012.236","volume":"32","author":"C Jin","year":"2013","unstructured":"Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2013;32:2179\u201388.","journal-title":"Oncogene"},{"key":"9260_CR20","doi-asserted-by":"crossref","unstructured":"Li W, Zhang N, Jin C, Long MD, Rajabi H, Yasumizu Y, et al. MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight. 2020;5.","DOI":"10.1172\/jci.insight.137112"},{"key":"9260_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14219-6","volume":"11","author":"Y Yasumizu","year":"2020","unstructured":"Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, et al. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020;11:338.","journal-title":"Nat Commun"},{"key":"9260_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtho.2023.10.017","volume":"19","author":"N Haratake","year":"2024","unstructured":"Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, et al. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC. J Thorac Oncol. 2024;19:434\u201350.","journal-title":"J Thorac Oncol"},{"key":"9260_CR23","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1158\/0008-5472.CAN-09-0523","volume":"69","author":"R Ahmad","year":"2009","unstructured":"Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009;69:7013\u201321.","journal-title":"Cancer Res"},{"key":"9260_CR24","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1038\/onc.2017.47","volume":"36","author":"A Bouillez","year":"2017","unstructured":"Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, et al. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017;36:4037\u201346.","journal-title":"Oncogene"},{"key":"9260_CR25","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","volume":"10","author":"P Dobosz","year":"2019","unstructured":"Dobosz P, Dzieci\u0105tkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019;10:2965.","journal-title":"Front Immunol"},{"key":"9260_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785091","volume":"12","author":"AP Shi","year":"2021","unstructured":"Shi AP, Tang XY, Xiong YL, Zheng KF, Liu YJ, Shi XG, et al. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. Front Immunol. 2021;12:785091.","journal-title":"Front Immunol"},{"key":"9260_CR27","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2024.14","volume":"26","author":"M Sz\u00e1nt\u00f3","year":"2024","unstructured":"Sz\u00e1nt\u00f3 M, Y\u00e9lamos J, Bai P. Specific and shared biological functions of PARP2 - is PARP2 really a lil\u2019 brother of PARP1? Expert Rev Mol Med. 2024;26:e13.","journal-title":"Expert Rev Mol Med"},{"key":"9260_CR28","first-page":"333","volume":"22","author":"R Iwata","year":"2020","unstructured":"Iwata R, Hyoung Lee J, Hayashi M, Dianzani U, Ofune K, Maruyama M, et al. ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma. Neuro Oncol. 2020;22:333\u201344.","journal-title":"Neuro Oncol"},{"key":"9260_CR29","doi-asserted-by":"crossref","unstructured":"Kanellis DC, Espinoza JA, Zisi A, Sakkas E, Bartkova J, Katsori AM, et al. The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. Sci Adv. 2021;7.","DOI":"10.1126\/sciadv.abf7561"},{"key":"9260_CR30","doi-asserted-by":"crossref","unstructured":"Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, et al. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3\/MUC1\/EGFR Signaling. Int J Mol Sci. 2021;22.","DOI":"10.21203\/rs.3.rs-137571\/v1"},{"key":"9260_CR31","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/nar\/25.16.3332","volume":"25","author":"B Shen","year":"1997","unstructured":"Shen B, Nolan JP, Sklar LA, Park MS. Functional analysis of point mutations in human flap endonuclease-1 active site. Nucleic Acids Res. 1997;25:3332\u20138.","journal-title":"Nucleic Acids Res"},{"key":"9260_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712045","volume":"11","author":"J Ye","year":"2021","unstructured":"Ye J, She X, Liu Z, He Z, Gao X, Lu L, et al. Eukaryotic Initiation Factor 4A-3: A Review of Its Physiological Role and Involvement in Oncogenesis. Front Oncol. 2021;11:712045.","journal-title":"Front Oncol"},{"key":"9260_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11033-024-09524-3","volume":"51","author":"M Wu","year":"2024","unstructured":"Wu M, Huang X, Wu B, Zhu M, Zhu Y, Yu L, et al. The endonuclease FEN1 mediates activation of STAT3 and facilitates proliferation and metastasis in breast cancer. Mol Biol Rep. 2024;51:553.","journal-title":"Mol Biol Rep"},{"key":"9260_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.04.019","volume":"45","author":"E Zhao","year":"2021","unstructured":"Zhao E, Zhou C, Chen S. Flap endonuclease 1 (FEN1) as a novel diagnostic and prognostic biomarker for gastric cancer. Clin Res Hepatol Gastroenterol. 2021;45:101455.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"9260_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02110-w","volume":"40","author":"Z Wang","year":"2023","unstructured":"Wang Z, Yong C, Fu Y, Sun Y, Guo Z, Liu SB, et al. Inhibition of FEN1 promotes DNA damage and enhances chemotherapeutic response in prostate cancer cells. Med Oncol. 2023;40:242.","journal-title":"Med Oncol"},{"key":"9260_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/1878-0261.12058","volume":"11","author":"L He","year":"2017","unstructured":"He L, Luo L, Zhu H, Yang H, Zhang Y, Wu H, et al. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer. Mol Oncol. 2017;11:640\u201354.","journal-title":"Mol Oncol"},{"key":"9260_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.15252\/embr.201439245","volume":"15","author":"BG Childs","year":"2014","unstructured":"Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 2014;15:1139\u201353.","journal-title":"EMBO Rep"},{"key":"9260_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41418-018-0114-7","volume":"26","author":"SH Jung","year":"2019","unstructured":"Jung SH, Lee M, Park HA, Lee HC, Kang D, Hwang HJ, et al. Integrin \u03b16\u03b24-Src-AKT signaling induces cellular senescence by counteracting apoptosis in irradiated tumor cells and tissues. Cell Death Differ. 2019;26:245\u201359.","journal-title":"Cell Death Differ"},{"key":"9260_CR39","doi-asserted-by":"crossref","unstructured":"Yamashita N, Long M, Fushimi A, Yamamoto M, Hata T, Hagiwara M, et al. MUC1-C integrates activation of the IFN-\u03b3 pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. J Immunother Cancer. 2021;9:e002115.","DOI":"10.1136\/jitc-2020-002115"},{"key":"9260_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01513-22","volume":"96","author":"Q Gao","year":"2022","unstructured":"Gao Q, Jiang M, Zhao Y, Li G, Yang C, Ren C, et al. eIF4A3 Promotes RNA Viruses\u2019 Replication by Inhibiting Innate Immune Responses. J Virol. 2022;96:e0151322.","journal-title":"J Virol"},{"key":"9260_CR41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1158\/1541-7786.MCR-22-0984","volume":"21","author":"W Yu","year":"2023","unstructured":"Yu W, Liang J, Fang T, Jiang J, Zhao R, Li R, et al. EIF4A3 Acts on the PI3K-AKT-ERK1\/2-P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma. Mol Cancer Res. 2023;21:713\u201325.","journal-title":"Mol Cancer Res"},{"key":"9260_CR42","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1038\/sj.emboj.7600272","volume":"23","author":"O Cordin","year":"2004","unstructured":"Cordin O, Tanner NK, Do\u00e8re M, Linder P, Banroques J. The newly discovered Q motif of DEAD-box RNA helicases regulates RNA-binding and helicase activity. Embo j. 2004;23:2478\u201387.","journal-title":"Embo j"},{"key":"9260_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1678907","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lu K, Xu Y, Xu S, Chu H, Fang X. Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies. Front Immunol. 2025;16:1678907.","journal-title":"Front Immunol"},{"key":"9260_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/sci\/1325262","volume":"2025","author":"P Wang","year":"2025","unstructured":"Wang P, Xu S, Guo Q, Zhao Y. Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques. Stem Cells Int. 2025;2025:1325262.","journal-title":"Stem Cells Int"},{"key":"9260_CR45","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47:D1211\u2013d7.","journal-title":"Nucleic Acids Res"},{"key":"9260_CR46","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y, et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2022;50:D1522\u2013d7.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09260-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:30:06Z","timestamp":1792150206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09260-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9260"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09260-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted in accordance with the principles of the Helsinki Declaration. All patients had signed an informed consent form permitting analyses of tissues. The study was approved by the Ethical Committee of the Affiliated Hospital of Yangzhou University (No.2024-YKL03-019). The animal study protocols and experimental procedures involving mice were approved by the Ethical Committee of Faculty of Medicine of Yangzhou University (No. 202403216).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"889"}}